Goldline Pharmaceutical Limited is engaged in the business of marketing and distribution of pharmaceutical products under its brand name “Goldline.” The company does not manufacture products in-house. Instead, it partners with third-party manufacturers who produce medicines based on the company’s market research, demand analysis, and product specifications.
The company’s product portfolio is divided into five major segments:
- Goldline Pharma: Includes 42 products catering to specialties such as physicians, orthopedics, ENT, chest physicians, general and specialty surgery, gastroenterology, neurology, and urology.
- Goldline Cardinal: Includes 54 products focused on specialty divisions such as physicians, diabetologists, endocrinologists, cardiologists, and general physicians.
- Goldline Aayushman: Includes 18 products designed for pediatricians, child specialists, neonatologists, and general practitioners.
- Goldline InLife: Includes 22 products for intensivists, critical care consultants, super specialty surgeons, and physicians.
- Goldline Wellness: Includes 10 products focused on supportive care for cancer therapy, aimed at improving the quality of life of cancer patients and survivors.
All products are marketed and sold under the Goldline brand through a distributor-based model. The company’s distributors further supply products to retailers and wholesalers, which form the main channel for reaching end users. The company currently has arrangements with 15 manufacturers and 7 distributors.
The company also provides material supply and procurement support to hospitals and healthcare partners through its promoter group entities, helping in procurement, distribution, and supply chain operations.
Goldline Pharmaceutical sells its products across multiple Indian states, including Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, Bihar, Chhattisgarh, Uttar Pradesh, and Goa.
Goldline Pharmaceutical IPO – Details
| IPO Opening Date | 12 May 2026 |
| IPO Closing Date | 14 May 2026 |
| Issue Type | Book Built Issue IPO |
| Issue Size | Total Issue: 27,00,000 Shares Worth ₹11.61 Crore Fresh Issue: 27,00,000 Shares Worth ₹11.61 Crore |
| Face Value | ₹10 per equity share |
| IPO Price | ₹41 – ₹43 per share |
| Market Lot | 3000 Shares |
| Min Order | 3000 Shares [ 1 Lot ] |
| Listing At | BSE SME |
| Registrar | Bigshare Services Pvt. Ltd. |
| QIB Shares Offered | 50% |
| NII Shares Offered | 15% |
| Retail Shares Offered | 35% |
Goldline Pharmaceutical IPO – Date Schedule
| IPO Open Date | 12 May 2026 |
| IPO Close Date | 14 May 2026 |
| Basis of Allotment | 15 May 2026 |
| Initiation of Refund | 18 May 2026 |
| Credit of Shares to Demat | 18 May 2026 |
| IPO Listing Date | 19 May 2026 |
| Cut-off time for UPI mandate confirmation | 5 PM on May 14, 2026 |
Goldline Pharmaceutical IPO – Lots Size & Price
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 2 | 6,000 | ₹2,58,000 |
| Retail (Max) | 2 | 6,000 | ₹2,58,000 |
| S-HNI (Min) | 3 | 9,000 | ₹3,87,000 |
| S-HNI (Max) | 7 | 21,000 | ₹9,03,000 |
| B-HNI (Min) | 8 | 24,000 | ₹10,32,000 |
Competitive Strength
- Experienced Promoters and Management Team with Industry Knowledge and a Track Record.
- Asset-light Business Model and Competitive Products.
- Scalable Business Model.
- Wide and Diverse Range of Product Offerings.
- Strong Supplier and Vendor Relationships.
- Established Distribution Network.
Company Promoters
- Amol Laxmikant Mujumdar
- Swapan Premprakash Khandelwal
Company Financials
| Period | Total Revenue | Total Expense | Profit After Tax | Total Borrowings |
|---|---|---|---|---|
| 31 March 2023 | ₹19.85 Cr | ₹19.45 Cr | ₹0.26 Cr | ₹10.83 Cr |
| 31 March 2024 | ₹23.57 Cr | ₹21.04 Cr | ₹1.81 Cr | ₹11.13 Cr |
| 31 March 2025 | ₹28.06 Cr | ₹24.20 Cr | ₹2.83 Cr | ₹11.03 Cr |
Key Performance Indicator
| KPI | Values (Mar 31, 2025) |
|---|---|
| ROE | 35.84% |
| ROCE | 38.46% |
| Debt/Equity | 1.50 |
| RoNW | 27.38% |
| PAT Margin | 10.10% |
| EBITDA Margin | 20.79% |
| Price to Book Value | 3.47 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 4.11 | 2.95 |
| P/E (x) | 10.47 | 14.56 |
Object Of The Issue
| Objects of the Issue | Expected Amount (in Crore) |
|---|---|
| Prepayment or repayment of all or a portion of certain outstanding borrowings availed by the company. | ₹8.90 |
| General corporate purposes. | – |
✅Strengths
- Strong focus on quality assurance with ISO 9001:2015 certification.
- Strategic location advantage at Himatnagar, Gujarat, near Rajasthan.
- Experienced management and team.
- Owned manufacturing facility, giving better control over production.
- Diversified product range for customized flexible packaging solutions.
⚠️Risks
- Loss of key managerial personnel may affect operations.
- High dependence on a few customers for revenue.
- Under-utilization of manufacturing capacity may affect performance.
- Trading revenue has increased, which may affect margins.
- Plastic/environmental regulations may impact business operations and costs.
Goldline Pharmaceutical IPO Promoter Holding
| Pre-Issue Share Holding | 79.70% |
| Post Issue Share Holding | – |
Goldline Pharmaceutical IPO Prospectus
- Goldline Pharmaceutical IPO DRHP
- Goldline Pharmaceutical IPO RHP
Company Contact Information
| Goldline Pharmaceutical Ltd. 3, F-1, Leela Apartment, Shilpa HSG Society, Near Saptagiri Nagar, Shanidham, Narendra Nagar, Nagpur, Maharashtra, 440015 Phone: +91 712 2786666 Email: info@goldlinepharma.in Website: https://www.goldlinepharma.in/ |
Goldline Pharmaceutical IPO Registrar
| Bigshare Services Pvt. Ltd. Phone: +91-22-6263 8200 Email: ipo@bigshareonline.com Website: https://ipo.bigshareonline.com/IPO_Status.html |
Goldline Pharmaceutical IPO Lead Manager(s)
| 1. Cumulative Capital Pvt. Ltd. |
Goldline Pharmaceutical IPO FAQ
| What is the Goldline Pharmaceutical IPO? Goldline Pharmaceutical IPO is an SME IPO. The issue is priced at ₹41 – ₹43 per equity share. The IPO is to be listed on BSE SME. |
| When will Goldline Pharmaceutical IPO open? The IPO is to open on 12 May 2026 for QIB, NII, and Retail Investors. |
| What is Goldline Pharmaceutical IPO Investors’ Portion? The investors’ portion for QIB – 50%, NII – 15%, and Retail – 35%. |
| What is the Goldline Pharmaceutical IPO Size? Goldline Pharmaceutical IPO size is ₹11.61 Crore. |
| What are the Goldline Pharmaceutical IPO Minimum and Maximum Lot Sizes for Retail Investors? The minimum bid is 6000 Shares for ₹2,58,000, while the maximum bid is 6000 Shares for ₹2,58,000. |
| What is the Goldline Pharmaceutical IPO Allotment Date? Goldline Pharmaceutical IPO allotment date is 15 May 2026. |
| What is the Goldline Pharmaceutical IPO Listing Date? Goldline Pharmaceutical IPO listing date is 19 May 2026. The IPO is to be listed on the BSE SME. |
